Seabelife SAS to develop next-gen dry AMD drug
French drug developer SeaBeLife SAS has bagged a €1.5m fund within the i-Nov 2024 innovation competition, which is part of the French government’s...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...
AstraZeneca to take over Fusion Therapeutics Inc
Fusion Pharmaceuticals Inc‘s acquisition for US$2bn upfront marks a major step forward in AstraZeneca delivering on its ambition to transform cancer...
Klineo raises €2m to speed up access to cancer trials
Digital health start-up Klineo SAS (Paris) has raised €2m to improve equity of access to clinical trials. Its AI-based platform connects doctors and...
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...